2m 2m 2m 2m 2m 2m 2m
Grace Therap (GRCE)
NASDAQ
$2.40+$0.007 (+0.29%)
Price as of Jun 23, 2026 7:56 PM EDT- $36.8MMarket Cap
- -20.33%1-Year Change
- BiotechnologyIndustry
Grace Therap (GRCE)
$2.40+$0.007 (+0.29%)
Annual
Quarterly
03/31/2026 | 03/31/2025 | 03/31/2024 | 03/31/2023 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | N/A N/A | 100.0M N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | 0 -100.00% | 100.0M N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | 252,000 -61.88% | 661,000 +27.61% | |
Research and Development Expense | -2.4M -74.71% | -9.5M +103.10% | -4.7M -53.04% | -10.0M +79.38% | |
Depreciation and Amortization Expense | 7,000 0.00% | 7,000 -36.36% | 11,000 -91.13% | 124,000 N/A | |
Total Operating Expenses | 8.7M +20.98% | 7.2M +11.44% | 6.4M -15.52% | 7.6M N/A | |
Operating Profit | -11.1M -33.59% | -16.7M +29.78% | -12.9M -75.36% | -52.2M +234.56% | |
Interest Income | 685,000 -3.66% | 711,000 -21.95% | 911,000 +270.33% | 246,000 +219.48% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 685,000 -3.66% | 711,000 -21.95% | 911,000 +270.33% | 246,000 +219.48% | |
Total Nonoperating Income and Expense | 1.6M -59.51% | 3.9M +313.42% | -1.8M -1,096.20% | 184,000 -96.41% | |
Income before Taxes | -9.5M -25.64% | -12.8M -13.06% | -14.7M -71.74% | -52.0M +396.52% | |
Income Taxes | -1.7M -46.86% | -3.2M +74.62% | -1.8M -80.80% | -9.5M +1,372.53% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -7.8M -18.55% | -9.6M -25.56% | -12.9M -69.71% | -42.4M +332.11% | |
Net Income from Continuing Operations Applicable to Common | -9.5M -25.64% | -12.8M -13.06% | -14.7M -71.74% | -52.0M +396.52% | |
Basic EPS and Net Income | -0.47 -40.51% | -0.79 -41.48% | -1.35 +42.11% | -0.95 +251.85% | |
Diluted EPS and Net Income | -0.47 -40.51% | -0.79 -41.48% | -1.35 +42.11% | -0.95 +251.85% | |
Basic Weighted Average Shares | 16.5M +36.60% | 12.1M +26.85% | 9.5M -78.64% | 44.6M +21.09% | |
Diluted Weighted Average Shares | 16.5M +36.60% | 12.1M +26.85% | 9.5M -78.64% | 44.6M +21.09% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 17.0M -23.30% | 22.1M -3.79% | 23.0M -17.47% | 27.9M -8.12% | |
Short-Term Investments | N/A N/A | N/A N/A | 0 -100.00% | 15,000 -99.89% | |
Cash and Cash Equivalents and Short-Term Investments | 17.0M -23.30% | 22.1M -3.79% | 23.0M -17.52% | 27.9M -36.12% | |
Total Current Assets | 17.4M -23.48% | 22.7M -5.41% | 24.0M -18.03% | 29.3M -35.67% | |
Accumulated Depreciation | 0 -100.00% | 1,000 -99.84% | 608,000 +6.67% | 570,000 N/A | |
Property and Plant and Equipment and Net | 8,000 -46.67% | 15,000 -37.50% | 24,000 -76.92% | 104,000 -99.50% | |
Total Long-Term Assets | 0 N/A | 0 -100.00% | 24,000 -99.80% | 12.2M -64.30% | |
Total Assets | 66.7M -7.42% | 72.0M -1.78% | 73.3M -7.36% | 79.1M -38.48% | |
Income Taxes Payable | 612,000 -73.53% | 2.3M -58.07% | 5.5M -24.95% | 7.3M -56.50% | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 2.1M +11.19% | 1.9M +14.61% | 1.7M -50.63% | 3.4M +4.63% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 1.2M -78.77% | 5.8M -62.53% | 15.4M +1.87% | 15.1M -55.55% | |
Total Liabilities | 2.8M -48.76% | 5.4M -53.42% | 11.6M +3.48% | 11.2M -45.12% | |
Retained Earnings | -228.5M +3.53% | -220.7M +4.53% | -211.1M +6.48% | -198.3M +27.23% | |
Total Stockholders Equity | 63.9M -4.07% | 66.6M +7.88% | 61.7M -9.14% | 68.0M -37.24% | |
Total Shares Outstanding | 16.0M +16.81% | 13.7M +45.95% | 9.4M -78.93% | 44.6M N/A | |
Cash Flow | |||||
Cash from Operating Activities | -8.9M -40.49% | -14.9M +20.85% | -12.3M -22.50% | -15.9M -7.67% | |
Capital Expenditures | N/A N/A | 0 -100.00% | 22,000 N/A | N/A N/A | |
Cash from Investing Activities | 0 N/A | 0 -100.00% | 104,000 -99.21% | 13.2M +473.45% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 3.7M -73.54% | 14.0M +90.68% | 7.4M +2,320.72% | 304,000 N/A | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | -52.15% N/A | |
Return on Assets | -11.24% -14.65% | -13.17% -21.91% | -16.86% -58.71% | -40.85% +297.45% | |
Return on Equity | -11.94% -19.90% | -14.91% -24.78% | -19.82% -58.84% | -48.15% +301.96% | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 8.10 -31.18% | 11.77 -17.46% | 14.26 +66.04% | 8.59 -38.52% | |
Cash Ratio | 7.91 -31.02% | 11.47 -16.05% | 13.66 +67.17% | 8.17 -12.19% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow